Robert J Devita

List of Publications by Year
in descending order

68 papers	2,073 citations	186265 28 h-index	276875 41 g-index
70 all docs	70 docs citations	70 times ranked	2385 citing authors

#	Article	IF	Citations
1	Small-molecule activation of SERCA2a SUMOylation for the treatment of heart failure. Nature Communications, 2015, 6, 7229.	12.8	102
2	Enantioselective total synthesis of neooxazolomycin. Journal of the American Chemical Society, 1990, 112, 4070-4072.	13.7	97
3	Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 9820-9825.	6.4	90
4	Novel synthesis of oxadiazoles via palladium catalysis. Tetrahedron Letters, 1998, 39, 3931-3934.	1.4	82
5	GLP-1 receptor agonists synergize with DYRK1A inhibitors to potentiate functional human Î² cell regeneration. Science Translational Medicine, 2020, 12, .	12.4	81
6	Asymmetric Synthesis of Chiral, Nonracemic Trifluoromethyl-Substituted Piperidines and Decahydroquinolines. Journal of the American Chemical Society, 1999, 121, 593-594.	13.7	77
7	Microscale High-Throughput Experimentation as an Enabling Technology in Drug Discovery: Application in the Discovery of (Piperidinyl)pyridinyl-1H-benzimidazole Diacylglycerol Acyltransferase 1 Inhibitors. Journal of Medicinal Chemistry, 2017, 60, 3594-3605.	6.4	65
8	Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human Î²-Cell Proliferation. Journal of Medicinal Chemistry, 2018, 61, 7687-7699.	6.4	58
9	Identification and initial structure-activity relationships of a novel non-peptide quinolone GnRH receptor antagonist. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2615-2620.	2.2	54
10	Potent antagonists of gonadotropin releasing hormone receptors derived from quinolone-6-carboxamides. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 443-447.	2.2	51
11	Direct syntheses of polyfused ring systems by intramolecular tandem palladium-ene/Heck insertion reactions. Journal of Organic Chemistry, 1991, 56, 6256-6257.	3.2	50
12	Investigation of the 4-O-alkylamine substituent of non-peptide quinolone GnRH receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 2621-2624.	2.2	50
13	Food colorants metabolized by commensal bacteria promote colitis in mice with dysregulated expression of interleukin-23. Cell Metabolism, 2021, 33, 1358-1371.e5.	16.2	49
14	A Potent, Nonpeptidyl 1H-Quinolone Antagonist for the Gonadotropin-Releasing Hormone Receptor. Journal of Medicinal Chemistry, 2001, 44, 917-922.	6.4	48
15	A Potent, Orally Bioavailable Benzazepinone Growth Hormone Secretagogue. Journal of Medicinal Chemistry, 1998, 41, 1716-1728.	6.4	44
16	Dissecting the Contributions of Cooperating Gene Mutations to Cancer Phenotypes and Drug Responses with Patient-Derived iPSCs. Stem Cell Reports, 2018, 10, 1610-1624.	4.8	43
17	Rational design of 4-[(methylsulfonyl)amino]benzamides as class III antiarrhythmic agents. Journal of Medicinal Chemistry, 1987, 30, 755-758.	6.4	41
18	Identification of Phe313 of the Gonadotropin-Releasing Hormone (GnRH) Receptor as a Site Critical for the Binding of Nonpeptide GnRH Antagonists. Molecular Endocrinology, 2000, 14, 671-681.	3.7	41

#	Article	IF	Citations
19	Synthesis of 4-Trifluoromethylated 2-Alkyl- and 2,3-Dialkyl-Substituted Azetidines. Organic Letters, 2003, 5, 4101-4103.	4.6	39
20	Structure-activity relationships in the amino acid sidechain of L-692,429. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1117-1122.	2.2	38
21	DYRK1A Inhibitors as Potential Therapeutics for Î²-Cell Regeneration for Diabetes. Journal of Medicinal Chemistry, 2021, 64, 2901-2922.	6.4	38
22	Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic Î²-cell proliferation activity. European Journal of Medicinal Chemistry, 2018, 157, 1005-1016.	5.5	36
23	Synthesis and Biological Validation of a Harmine-Based, Central Nervous System (CNS)-Avoidant, Selective, Human Î²-Cell Regenerative Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase A (DYRK1A) Inhibitor. Journal of Medicinal Chemistry, 2020, 63, 2986-3003.	6.4	36
24	A mild four-carbon homologation of aldehydes to E,E-dienamines. Tetrahedron Letters, 1990, 31, 307-310.	1.4	35
25	Pharmacologic and genetic approaches define human pancreatic Î² cell mitogenic targets of DYRK1A inhibitors. JCI Insight, 2020, 5, .	5.0	35
26	The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical species. Journal of Lipid Research, 2011, 52, 1150-1161.	4.2	34
27	Discovery of MK-4409, a Novel Oxazole FAAH Inhibitor for the Treatment of Inflammatory and Neuropathic Pain. ACS Medicinal Chemistry Letters, 2014, 5, 717-721.	2.8	34
28	2-Aminoquinoline melanin-concentrating hormone (MCH)1R antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5270-5274.	2.2	32
29	Discovery of MK-3168: A PET Tracer for Imaging Brain Fatty Acid Amide Hydrolase. ACS Medicinal Chemistry Letters, 2013, 4, 509-513.	2.8	31
30	Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice. Science Translational Medicine, 2021, 13, eabf7084.	12.4	28
31	Human Beta Cell Regenerative Drug Therapy for Diabetes: Past Achievements and Future Challenges. Frontiers in Endocrinology, 2021, 12, 671946.	3.5	24
32	Fused bicyclic pyrrolizinones as new scaffolds for human NK1 antagonists. Bioorganic and Medicinal Chemistry, 2008, 16, 2156-2170.	3.0	23
33	Syntheses and structureâ€“activity relationship studies of piperidine-substituted quinolones as nonpeptide gonadotropin releasing hormone antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 1795-1798.	2.2	22
34	Potent, Brain-Penetrant, Hydroisoindoline-Based Human Neurokinin-1 Receptor Antagonists. Journal of Medicinal Chemistry, 2009, 52, 3039-3046.	6.4	21
35	Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety. ACS Medicinal Chemistry Letters, 2014, 5, 1082-1087.	2.8	21
36	Identification of CNS-Penetrant Aryl Sulfonamides as Isoform-Selective Na_V1.6 Inhibitors with Efficacy in Mouse Models of Epilepsy. Journal of Medicinal Chemistry, 2019, 62, 9618-9641.	6.4	21

#	Article	IF	Citations
37	DHTKD1 and OGDH display substrate overlap in cultured cells and form a hybrid 2-oxo acid dehydrogenase complex in vivo. Human Molecular Genetics, 2020, 29, 1168-1179.	2.9	21
38	Benzolactam growth hormone secretagogues: Carboxamides as replacements for the 2â€²-tetrazole moiety of L-692,429. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2249-2254.	2.2	20
39	Quinolones as gonadotropin releasing hormone (GnRH) antagonists: simultaneous optimization of the C(3)-aryl and C(6)-substituents. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 1723-1727.	2.2	20
40	Pyrrolidine-carboxamides and oxadiazoles as potent hNK1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5310-5315.	2.2	20
41	Fused tricyclic pyrrolizinones that exhibit pseudo-irreversible blockade of the NK1 receptor. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 5925-5932.	2.2	19
42	Broad Spectrum Inhibitor of Influenza A and B Viruses Targeting the Viral Nucleoprotein. ACS Infectious Diseases, 2018, 4, 146-157.	3.8	19
43	Synthesis and antiarrhythmic activity of novel 3-alkyl-1-[.omega.-[4-[(alkylsulfonyl)amino]phenyl]-.omega.-hydroxyalkyl]-1H-imidazolium salts and related compounds. Journal of Medicinal Chemistry, 1987, 30, 696-704.	6.4	17
44	Deletion of 2â€aminoadipic semialdehyde synthase limits metabolite accumulation in cell and mouse models for glutaric aciduria type 1. Journal of Inherited Metabolic Disease, 2020, 43, 1154-1164.	3.6	17
45	Spiroimidazolidinone NPC1L1 inhibitors. 1: Discovery by 3D-similarity-based virtual screening. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 2965-2968.	2.2	16
46	Spiroimidazolidinone NPC1L1 inhibitors. Part 2: Structureâ€“activity studies and in vivo efficacy. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6929-6932.	2.2	16
47	Synthesis of the fused bicyclic lactam-lactone terminus of neooxazolomycin by a novel dianion cyclocondensation. Tetrahedron Letters, 1988, 29, 2521-2524.	1.4	15
48	4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorganic and Medicinal Chemistry Letters, 2006, 16, 5275-5279.	2.2	14
49	Encounter and React: Computer-Guided Design of Covalent Inhibitors. Cell Chemical Biology, 2019, 26, 6-8.	5.2	14
50	Inhibition and Crystal Structure of the Human DHTKD1-Thiamin Diphosphate Complex. ACS Chemical Biology, 2020, 15, 2041-2047.	3.4	14
51	Structure-activity relationships of the non-peptidyl growth hormone secretagogue L-692,429. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 2709-2714.	2.2	13
52	The discovery of potent, selective, and orally bioavailable hNK1 antagonists derived from pyrrolidine. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5191-5198.	2.2	13
53	Structureâ€“Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human Î²-Cell Proliferation. Molecules, 2020, 25, 1983.	3.8	13
54	Benzolactam growth hormone secretagogues: replacements for the 2â€²-tetrazole moiety of L-692,429. Bioorganic and Medicinal Chemistry Letters, 1994, 4, 1807-1812.	2.2	12

#	Article	IF	Citations
55	Heterocyclic analogs of the benzolactam nucleus of the non-peptidic growth hormone secretagogue L-692,429. Bioorganic and Medicinal Chemistry Letters, 1995, 5, 1281-1286.	2.2	11
56	2-[(3aR,4R,5S,7aS)-5-{(1S)-1-[3,5-Bis(trifluoromethyl)phenyl]-2-hydroxyethoxy}-4-(2-methylphenyl)oc A Potent Human NK₁ Receptor Antagonist with Multiple Clearance Pathways. Journal of Medicinal Chemistry, 2013, 56, 5940-5948.	6.4	11
57	Potent DGAT1 Inhibitors in the Benzimidazole Class with a Pyridyl-oxy-cyclohexanecarboxylic Acid Moiety. ACS Medicinal Chemistry Letters, 2013, 4, 773-778.	2.8	11
58	Substituted fused bicyclic pyrrolizinones as potent, orally bioavailable hNK1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2007-2012.	2.2	10
59	Identification of neutral 4-O-alkyl quinolone nonpeptide GnRH receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5599-5603.	2.2	9
60	Aminoquinoline Melanin-Concentrating Hormone 1-Receptor (MCH1-R) Antagonists. Current Topics in Medicinal Chemistry, 2007, 7, 1433-1439.	2.1	9
61	Identification and Characterization of Sebaceous Gland Atrophy-Sparing DGAT1 Inhibitors. PLoS ONE, 2014, 9, e88908.	2.5	9
62	Inhibitors of cullin-RING E3 ubiquitin ligase 4 with antitumor potential. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	9
63	Multiple strategies for the preparation of a sulfur-35 labeled NPC1L1 radioligand. Bioorganic and Medicinal Chemistry Letters, 2009, 19, 5033-5036.	2.2	6
64	Tetrahydroindolizinone NK1 antagonists. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 2354-2358.	2.2	6
65	Small molecule mimetics of GHRP-6. Expert Opinion on Investigational Drugs, 1997, 6, 1839-1843.	4.1	5
66	Development of indazole mineralocorticoid receptor antagonists and investigation into their selective late-stage functionalization. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1854-1858.	2.2	5
67	Synthesis of oxaspiropiperidines as a strategy for lowering logD. Tetrahedron Letters, 2011, 52, 6457-6459.	1.4	4
68	IUPAC-Richter Prize Call for Nominations. Journal of Medicinal Chemistry, 2021, 64, 13937-13937.	6.4	0